Fresh analysis reveals that people who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end conventional lifestyle plans.
Published data in a prominent medical journal points out that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Users purchasing such medications should be cognizant of the risk of rapid rebound weight gain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to starting mass within about 18 months.
Comparing Therapies
The study, which looked at dozens of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists point out that individuals who lose weight through lifestyle changes alone generally see a slower weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Doctors propose the mechanism of the injections is key to understanding the accelerated weight return.
The injections copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than normal could lead to the body to produce less of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication leads to hunger is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the high risk of weight regain, the therapy might need to be long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "underscore the persistent character of excess weight," similar to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the medication describe a intense return of appetite.
"It felt as if a switch activating and I was suddenly ravenous," described an individual.
This difficulty is worsened if users have not developed lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while the jabs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated behavioural changes.
